Axa S.A. Grows Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

AXA S.A. boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 571,538 shares of the biotechnology company's stock after buying an additional 8,874 shares during the period. AXA S.A. owned 0.30% of BioMarin Pharmaceutical worth $37,567,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of BioMarin Pharmaceutical by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 19,372,185 shares of the biotechnology company's stock valued at $1,273,334,000 after acquiring an additional 93,531 shares during the period. Dodge & Cox grew its position in BioMarin Pharmaceutical by 6.1% during the 4th quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company's stock worth $969,270,000 after purchasing an additional 847,917 shares during the last quarter. Capital Research Global Investors increased its stake in BioMarin Pharmaceutical by 23.8% in the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock valued at $853,944,000 after purchasing an additional 2,496,817 shares during the period. Norges Bank purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $234,645,000. Finally, Geode Capital Management LLC boosted its stake in shares of BioMarin Pharmaceutical by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 3,288,778 shares of the biotechnology company's stock worth $215,784,000 after buying an additional 28,728 shares during the period. Hedge funds and other institutional investors own 98.71% of the company's stock.

Insider Activity

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total transaction of $92,618.40. Following the transaction, the chief accounting officer now directly owns 16,955 shares of the company's stock, valued at $1,212,621.60. The trade was a 7.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold 2,912 shares of company stock valued at $202,244 in the last three months. Corporate insiders own 0.85% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on BMRN. Piper Sandler upped their price objective on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research note on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $90.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Scotiabank raised their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 20th. UBS Group raised their price target on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $93.45.

BioMarin Pharmaceutical Trading Down 0.5 %

Shares of BMRN stock traded down $0.32 during trading hours on Wednesday, hitting $59.32. 1,295,231 shares of the company were exchanged, compared to its average volume of 1,861,234. BioMarin Pharmaceutical Inc. has a 1 year low of $52.93 and a 1 year high of $94.85. The firm has a fifty day moving average of $65.52 and a 200 day moving average of $65.62. The firm has a market cap of $11.32 billion, a PE ratio of 26.96, a PEG ratio of 0.61 and a beta of 0.27. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. The business had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. Analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.